GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Weekly Top Insider Buys: Health Care REIT, Human Genome Sciences, Legg Mason, Conseco Inc., Universal Display Corp., and Analogic Corp.

December 29, 2009 | About:
guruek

gururk

7 followers
Weekly highlight of top insider buys: Health Care REIT Inc. (HCN), Human Genome Sciences Inc. (HGSI),Legg Mason Inc. (LM),Conseco Inc. (CNO), Universal Display Corp. (PANL), and Analogic Corp. (ALOG)

Health Care REIT Inc. (HCN): Director Thomas J Derosa Bought 2,200 Shares

Director of Health Care REIT Inc., Thomas J Derosa, bought 2,200 shares on 12/23/09 at an average price of $46.19.

Health Care REIT Inc. is a self-administered, real estate investment trust that invests in health care facilities, primarily nursing homes, assisted living facilities and retirement centers. The company's investments are typically structured using operating leases or mortgage loans which are normally secured by guarantees and/or letters of credit. Health Care Reit Inc. has a market cap of $5.68 billion; its shares were traded at around $46.19 with a P/E ratio of 13.8 and P/S ratio of 10.3. The dividend yield of Health Care Reit Inc. stocks is 5.9%. Health Care Reit Inc. had an annual average earning growth of 3.6% over the past 10 years. GuruFocus rated Health Care Reit Inc. the business predictability rank of 2.5-star.

On November 4, Health Care Reit Inc. reported results for the third quarter of 2009. Included were completed 3Q09 and year-to-date gross new investments totaling $156.3 million and $507.7 million, respectively and received $177.4 million in proceeds on property sales and loan payoffs year-to-date, generating $26.9 million of gains.

Human Genome Sciences Inc. (HGSI): Director Jurgen Drews Bought 1,100 Shares

Director of Human Genome Sciences Inc., Jurgen Drews, bought 1,100 shares on 12/22/09 at an average price of $30.77.

Human Genome Sciences is a biopharmaceutical company with a pipeline of novel compounds in clinical development, including drugs to treat such diseases as hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. Its mission is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody products. Human Genome Sciences Inc. has a market cap of $5.55 billion; its shares were traded at around $30.77 with and P/S ratio of 114.7. Human Genome Sciences Inc. had an annual average earning growth of 24.1% over the past 10 years.

On October 29, HGS reported that revenues for the quarter ended September 30, 2009, increased to $18.8 million, compared with revenues of $11.7 million for the same period in 2008. Net loss for the quarter ended September 30, 2009, decreased to $49.0 million ($0.32 per share), compared with a net loss for the third quarter of 2008 of $74.2 million ($0.55 per share).

In September, Sell:: CFO Timothy C Barabe sold 35,273 shares of HGSI stock and the price of the stock increased by 53.85%.Buy:: Director Jurgen Drews and Buy:: Director Ngoc Tuan Ha both bought shares in December; Sell:: Senior Vice President Susan D. Bateson and Sell:: Exec VP & CCO Barry Labinger sold shares the same month.

Legg Mason Inc. (LM): Director Nelson Peltz Bought 1,052,830 Shares

Director of Legg Mason Inc., Nelson Peltz, bought 1,052,830 shares during the past week at an average price of $30.39.

Legg Mason, Inc. is a holding company which, through its subsidiaries, is principally engaged in providing asset management, securities brokerage, investment banking and related financial services to individuals, institutions, corporations and municipalities. Legg Mason Inc. has a market cap of $4.9 billion; its shares were traded at around $30.39 with and P/S ratio of 1.4. The dividend yield of Legg Mason Inc. stocks is 0.4%. Legg Mason Inc. had an annual average earning growth of 9.6% over the past 10 years.

On October 22, Legg Mason, Inc. reported its operating results for the second fiscal quarter ended September 30, 2009. The company reported net income of $45.8 million, or $0.30 per diluted share, as compared to net income of $50.1 million, or $0.35 per diluted share, in the first fiscal quarter of 2010.

Legg Mason Inc. is in the portfolios of six Gurus: George Soros, John Keeley, Brian Rogers, Dodge & Cox, Ronald Muhlenkamp, and Robert Olstein.

This month, Buy:: Director Nelson Peltz bought 230,000 shares of LM stock and the price has increased by over 3%. Sell:: Director James E Ukrop sold 9,000 shares in July; the price has increased over 12%.

Conseco Inc. (CNO): Director Roger Keith Long Bought 400,000 Shares

Director of Conseco Inc., Roger Keith Long, bought 400,000 shares on 12/22/09 at an average price of $5.08.

Conseco, Inc. is one of middle America's leading sources for supplemental health insurance, life insurance and annuities. Conseco Inc. has a market cap of $1.03 billion; its shares were traded at around $5.08 with a P/E ratio of 5.4 and P/S ratio of 0.2.

On Nov. 4, Conseco Inc. reported results for third quarter 2009. Results included a net income of $15.4 million, compared to a net loss of $183.3 million in 3Q08 (including $38.9 million of net realized investment losses and valuation allowance for deferred tax assets in 3Q09 vs. $241.6 million of net realized investment losses and losses related to discontinued operations in 3Q08).

Conseco Inc. is currently in the portfolios of seven Gurus: John Paulson, John Keeley, George Soros, David Tepper, Richard Pzena, Michael Price, and Hotchkis & Wiley.

2009, which is less than 0.01% of the $4.41 billion portfolio of Soros Fund Management LLC.

This month, Buy:: Director Roger Keith Long bought 400,000 shares of CNO stock. The price of the stock has increased by 6.95% since.

Universal Display Corp. (PANL): Director Lawrence Lacerte Bought 12,651 Shares

Director of Universal Display Corp., Lawrence Lacerte, bought 12,651 shares on 12/22/09 at an average price of $13.36.

Universal Display Corporation is located in the Princeton Crossroads Corporate Center in Ewing, New Jersey, minutes away from its research partner at Princeton University. Universal Display's state-of-the-art facility is designed to further technology and materials development, technology transfer to manufacturing partners and work with customers to develop OLED products that meet their needs. Universal Display Corp. has a market cap of $491.1 million; its shares were traded at around $13.36 with and P/S ratio of 44.4. Universal Display Corp. had an annual average earning growth of 3.6% over the past 10 years.

On November 8, Universal Display Corporation reported results for the third quarter of 2009. Revenues for the third quarter of 2009 were $5,145,393, compared to $2,625,639 for the third

quarter of 2008.

This month, Buy:: Director Lawrence Lacerte bought 12,651 shares of PANL stock and the price increased by over 7%. He also bought shares in September and August. Sell:: VP of Tech Commercialization Janice K Mahon sold 7,500 shares in September; the price has increased over 10%.

Analogic Corp. (ALOG): Director Kevin C Melia Bought 1,250 Shares

Director of Analogic Corp., Kevin C Melia, bought 1,250 shares on 12/22/09 at an average price of $36.2.

Analogic Corporation conceives, designs, manufactures, and sells standard and customized high-precision data acquisition, signal and imaging processing based medical imaging and industrial systems and subsystems. Analogic Corp. has a market cap of $463.7 million; its shares were traded at around $36.2 with a P/E ratio of 78.6 and P/S ratio of 1.2. The dividend yield of Analogic Corp. stocks is 1.1%. Analogic Corp. had an annual average earning growth of 61.5% over the past 5 years.

On December 9, Analogic Corporation reported results for the first fiscal quarter ended October 31, 2009. Revenues were $95.4 million, compared with fourth quarter revenues of $98.3 million and the prior fiscal year's first quarter revenues of $101.6 million. Reported net income for the first quarter of fiscal 2010 was $26,000, or $0.00 per diluted share, compared with a loss of ($0.3) million, or ($0.02) per diluted share, in the fourth quarter of fiscal 2009 and income of $0.3 million, or $0.02 per diluted share, for the prior year's first quarter.

This month, Buy:: Director Kevin C Melia bought 1,250 shares of ALOG stock and the price of the stock has decreased by 0.47% since.[b][/b]

For the complete list of stocks that bought by their company executives, go to: Insider Buys.


Rating: 3.5/5 (4 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide